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Abstract
Introduction: Daytime drooling is experienced by around 50% of Parkinson’s patients, who fail to swallow saliva in
sufficient volume or regularity, despite normal production. This research explored the feasibility and acceptability of using
a cueing device, to improve drooling.
Methods: During a four-week intervention, 28 participants were asked to use a cueing device for 1 h per day. During this
time, the device vibrated once-per-minute, reminding the participant to swallow their saliva. A daily diary was used to
collect self-report around swallowing severity, frequency, and duration. This was filled out by participants for one week
before, four weeks during and for one week immediately after intervention. Diaries were also collected for one week
during a follow up, carried out four weeks after intervention finished.
Results: Participants self-reported benefits in drooling severity (p¼ 0.031), frequency (p 0.001), and duration
(p¼ 0.001) after using the device. Improvements were maintained at follow up. Twenty-two participants explicitly
reported a positive benefit to their drooling during exit interview. All felt the intervention and device were acceptable
and usable.
Conclusions: Using a cueing device for one month had perceived benefit to drooling severity, frequency and duration in
patients with Parkinson’s. Participants accepted the device and treatment protocol.
Keywords
Assistive technology, human factors, rehabilitation devices, self-care, therapeutic value
Date received: 9 August 2018; accepted: 27 April 2019
Introduction
Sialorrhoea, also termed drooling or ptyalism, is
reported as a common symptom of Parkinson’s. In
some studies, drooling is reported to be an issue in up
to 70% of participants, especially if one takes into
account nocturnal drooling and increasing severity of
Parkinson’s.1–4 Saliva is vital for good oral health.
Impaired production of, or loss of saliva through drool-
ing exposes individuals to a range of negative effects,
from mild annoyance at perceived lack or excess of
saliva in the mouth, to major health and psychosocial
issues. Saliva helps regulate oral pH and microbiotic
homeostasis.5 The antimicrobial, antiviral, and antifun-
gal properties of saliva aid oral cleansing, protect
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against infection, and support tissue repair. Saliva
serves as a buffer against noxious substances. It lubri-
cates the oral cavity, thereby supporting formation and
transport of the food bolus to the pharynx for swallow-
ing. It acts as a first stage in digestion and stimulates
interaction with chemosensory receptors to aid taste
and smell perception. It supports smooth movement
of the tongue and lips for speech. If saliva is lost
through drooling the person with Parkinson’s is at
risk of lowered resistance to infection, poor oral
health, and added problems with swallowing and
speech. Dry mouth—a common consequence of saliva
loss—is associated with risks of ulceration, tooth decay,
gingivitis, candidiasis, halitosis, and perioral dermato-
logical issues.6,7 In many societies, the effects of drool-
ing (e.g., odor, stained clothes, constant wiping) are
socially frowned upon. In this way, drooling may influ-
ence psychosocial health for the pwPD and produce an
added burden for the carer (e.g., washing clothes;
restricted social life).8–10
In Parkinson’s drooling is associated not with excess
production of saliva, but principally with muscle rigid-
ity and bradykinesia of the facial, tongue, and lip mus-
cles.11–13 People with Parkinson’s Disease (pwPD) who
experience drooling fail to swallow saliva in sufficient
volume or regularity, despite a normal amount of saliva
production.11,12 This leads to pooling of saliva in the
mouth and risk of anterior loss. In addition to the
impaired swallow mechanism in Parkinson’s, the dys-
autonomia associated with the condition, as well as
changes in sensory perception of food that affect sali-
vation (smell, taste, vision) may complicate the pic-
ture.5,7 Cognitive factors may also play a role.
Reynolds et al.,14 found an association between swal-
lowing frequency and drooling severity, in particular
during states of distraction.
Most current pharmaceutical treatments for drooling
in Parkinson’s aim to decrease saliva production.
However, there are potential complications associated
with their use. Firstly, as mentioned previously, lack of
saliva can cause oral health problems (e.g., gingivitis,
tooth destruction, tongue crusting).15 Secondly, drug
treatments such as sublingual atropine can lead to ser-
ious cognitive side effects, such as memory impairment
and/or hallucinations.16 Botulinum toxin injection into
the salivary glands can be painful and must be repeated
every three to six months. In addition, this carries some
risk of masseter and pharyngeal muscle weakness that
can both impact on chewing and swallowing.Meningaud
et al.15 extensively reviewed the modalities of treatment
for drooling problems and maintained that it is import-
ant to propose, where feasible, non-invasive treatment
options, such as behavioral cueing methods, before drug
or surgical therapy is considered. Recent major guide-
lines underline the importance of this strategy.17
Cueing has been employed to successfully improve
aspects of impaired activities in Parkinson’s, such as
gait.18–21 Cueing generally relies on the implementation
of a system of temporal cues, where participants are
provided with time-controlled auditory or haptic
prompts to instigate or modify a behavior.
The concept of temporal cueing as a treatment for
drooling has been built on previous work, which has
shown success of cueing, for example in gait training
for Parkinson’s.18 The belief is that the training of a
metronomic cue brings about the execution of a new
motor plan, which facilitates walking and suppresses
the impaired motor plan currently inhibiting the
intended movement.19–21 There is a level of automati-
city in the complex movements of both walking and
swallowing of saliva that link these two symptoms
together and allow for cross comparison of motor
theory. Both are triggered, patterned responses invol-
ving automated neural processes that generally do not
require conscious thinking for carrying out the activity.
However, in the case of Parkinson’s, these automatic
movements can become impeded when difficulties with
motor initiation arise. In terms of neurophysiology,
cueing is believed to suppress pathological basal ganglia
activity through activation of corticostriatal path-
ways.19 That is to say, the cue causes the initiation of
an alternative pathway in the brain, also linked to
motor activity, which brings about the initiation of
movement that has been halted.
The feasibility of cue provision to improve drooling
has been minimally studied. Marks et al.,22 used a
(now) commercially available device, in the form of a
brooch, which emitted an auditory cue (a short ‘‘beep’’)
at regular intervals to remind the wearer to swallow.
They found this yielded positive results for participants
(n¼ 6). Although the device was found to be effective
for the control of drooling problems, their small sample
size did not provide sufficient information around the
effectiveness of the intervention on a wider population
of people with Parkinson’s, nor did the authors discuss
the acceptability of the technology they trialed with
their participants. A further study by Marron et al.23
showed that wearers of the same drooling brooch
reported several aspects that reduced its acceptability.
For example, hearing impaired participants could not
use the device, yet the auditory cue was also a source
for concern for others in the environment, since the
beep attracted attention when worn, drawing into ques-
tion its social acceptability. The product used also
incorporated a switch to turn the device on and off.
Some users required assistance to operate this due to
their impaired fine motor skills.
In response to these drawbacks, we developed a
simple-to-use wrist-worn digital cueing device, the
Parkinson’s Disease Cueing Device (PDCue)
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(Figure 1). This was iteratively designed with pwPD
and their caregivers.24 This early study established
usability and motor and social acceptability of the
device we employed; that it was usable even by individ-
uals with marked fine motor and sensory difficulties;
and that a vibratory cue was preferable to an auditory
cue.24 The device delivers a silent vibratory cue, once
per minute when switched on, to remind the person to
swallow. The once per minute setting was decided upon
in accordance with previous research which established
daytime non-stimulated swallowing frequency in
healthy adults of around one swallow per minute.25
This was also the preferred interval selected by
Marron et al.23 in their study. There is, as yet, no lit-
erature relating to the swallowing rate of pwPD.
The purpose of the pilot study presented here was to
explore the feasibility and acceptability of using this
novel cueing device to help pwPD to self-manage
their drooling, and to establish whether there was evi-
dence of an effect on drooling severity and frequency
when wearing the PDCue. We also wanted to explore
some practicalities relating to recruitment and retention
of participants into the study, and how appropriate our
outcomes measures were, in order to inform the trial
design of any larger scale studies which might arise.
Methods
Experimental design
This study employed quantitative methods to examine
for possible effects of the cueing device on perceived
drooling severity and frequency. It used qualitative
methods (semi-structured exit interview) to establish
opinions of participants on the acceptability and feasi-
bility of the intervention program, and experiences of
using the PDCue.
Participants and recruitment
The UK based study was approved by the Newcastle
and North Tyneside National Research Ethics Service
Committee (reference: 11/NE/0257). Informed written
consent was obtained from all participants in the study.
All study data were collected by employees of
Northumbria Healthcare NHS Foundation Trust,
who were responsible for the organization of the pro-
ject. Participants were primarily recruited via the regu-
lar Parkinson’s clinics at Northumbria Healthcare
NHS Foundation Trust, but participants from
Participant Identification Centers in Sunderland,
Gateshead and Newcastle were also included.
Potential participants were identified by clinical staff
and then contacted by a researcher via telephone with
further information. Written information sheets were
then sent to those who expressed sustained interest
and, following a one-week period, participants were
visited in their homes to obtain informed consent.
Inclusion criteria were (1) anyone with a diagnosis of
Idiopathic Parkinson’s (stages I–III in Hoehn and Yahr
scale26), in accordance with the UK Parkinson’s Brain
Bank criteria,27 (2) an acknowledged daytime drooling
problem, either observed by a clinical professional
within a Parkinson’s Disease clinic or through patient
self-report, and (3) an ability to understand and
respond to the instructions given in the study.
Exclusion criteria were (1) currently receiving pharma-
ceutical treatment for drooling and (2) insufficient dex-
terity with which to use the device.
A full case history was taken from each participant
regarding their Parkinson’s, drooling, and history of
swallowing difficulties. The Mini Mental State Exam28
and Montreal Cognitive Assessment Test were con-
ducted for screening purposes of cognitive impair-
ment.29 The Unified Parkinson’s Disease Rating
Scales (UPDRS) II and III30 were conducted to gain
an indication of overall disease state. All assessments
were performed by the same researcher in the partici-
pant’s own home.
Participants were randomly allocated to either an
immediate intervention group (n¼ 17) or a delayed
intervention group (n¼ 11). This was to provide prelim-
inary data for comparison of treatment vs. no treat-
ment. The delayed group did not commence
intervention until after they had completed a four-
week period of no intervention. The randomization
protocol was predetermined using an online random
number generator (www.randomizer.org/). The num-
bers were arranged into consecutive order creating a
sequence for randomizing individuals (e.g., 1-immedi-
ate, 2-immediate, 3-delayed). If a participant left the
study, their group assignment (immediate or delayed)
was added to the end of this list to be filled by later
recruits. We aimed for a 1:1 ratio, with a target recruit-
ment of 30 participants (15 in each group). We fulfilled
the capacity of the intervention group, but time restric-
tions meant that we were unable to complete a delayed
Figure 1. The cueing device.
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start for the final two participants we had recruited. As
such, we entered them into the intervention group leav-
ing final numbers of 17 immediate and 11 delayed par-
ticipants. This is a limitation of the study and is
discussed further in the limitations section.
Measurements
The ‘‘saliva’’ subset of questions from the Radboud
Oral Motor Inventory for Parkinson’s Disease
(ROMP–Saliva),31 and the UPDRS 2.2 subtest for
saliva30 were conducted with each participant at: one
week before commencing use of the cueing intervention
(assessment point 1), one week immediately after fin-
ishing the intervention (assessment point 2), and four
weeks later at a follow up appointment (assessment
point 3). For participants in the delayed start group,
an additional assessment was collected four weeks prior
to the immediately pretreatment assessment (assess-
ment point 0). Figure 2 illustrates the time line.
ROMP-S is a validated tool31 for use with pwPD. It
is derived from the unvalidated Drooling Frequency
and Severity Scale (DFSS)32 originally drawn up for
children with cerebral palsy but employed in several
other populations. It was slightly modified for
ROMP-S, in particular by adding the option to score
that one is troubled by (perceived) accumulation of
saliva without actually drooling. The nine items, rated
on 5-point ordinal scales that describe gradations of
drooling activity, cover: day and nighttime frequency
and severity of drooling, effects on speech and eating
and drinking, how frequently one has to wipe away
saliva, limitations on daily activity and social participa-
tion, and overall impact.
UPDRS item 2.2 is a 5 point descriptive ordinal scale
ranging from 0 to 4; no drooling (0), excess saliva but
no loss (1), nighttime but not awake drooling (2),
awake drooling but wiping not necessary (3), severe
drooling with constant wiping/wet clothes (4).
At each assessment point, participants completed a
seven-day drooling severity, frequency, and duration
diary. Participants monitored their drooling over the
course of one self-selected hour per day when they
would typically drool (e.g., after meal times, in the
morning). Following Hauser et al.33 participants com-
pleted 100mm visual analogue scales (VASs). They
placed a cross on a 100-mm line (with 0mm being
‘‘no problem’’ and 100mm being ‘‘as bad as can be’’)
to indicate the number of separate incidents they felt
that drooling occurred (frequency), how long in min-
utes they felt drooling occurred (duration), and how
severe they felt drooling was (severity). This method
reflects standardized methods of monitoring using
paper diaries employed in other medical research
(e.g., Montgomery and Reynolds34 and Stone et al.35).
Finally, an exit interview was carried out with each
individual to gather qualitative feedback on the partici-
pants’ experiences. A semi-structured approach was
taken to probe; (a) experiences of drooling before
taking part in the study; (b) experiences of drooling
after taking part in the study; and (c) perceptions
around the acceptability, worthwhileness, and effective-
ness of the PDCue as a way to self-manage their
drooling.
Intervention
All participants were visited at home and received a
verbal and practical tutorial on how to use the cueing
device. They were asked to use the device for one hour a
day, for a total of four weeks, at a time when drooling
was an issue for them. Participants were asked to not
use the device during the hour that they were self-
reporting their drooling on the daily diary.
Data processing and analysis
Quantitative data were analyzed using the IBM SPSS
statistical software suite (v.22, IBM Corp, Armonk,
NY). For data collected at the ordinal, interval or
ratio level, normality of distribution was checked by
inspection of histograms and using the Shapiro–Wilk
Figure 2. Visualisation of the assessment schedule.
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and Kolmogorov–Smirnov tests.36 Data were summar-
ized using statistics appropriate to the level of the data
(e.g., median, interquartile range, frequency). In infer-
ential analysis, the Wilcoxon signed ranks test or
Mann–Whitney U test was applied to ordinal, interval
or ratio data, and the Chi-squared test to categorical
data. For analysis across all 28 participants of change
in scores from pre- to post-treatment (assessment
points 1 and 2), and from pre-treatment to follow-up
(assessment points 1 and 3) for the same variable, the
Bonferroni correction was applied, setting significance
at 2.5%. For all other inferential tests significance was
set at 5%. Two-tailed tests were used throughout.
A repeated measures design looked at both between
(delayed intervention vs. immediate intervention) and
within-group differences (all participants combined to
compare baseline pre-treatment, termination of treat-
ment, and follow-up outcomes).
Qualitative data collected during the exit interviews
were audio-recorded and transcribed verbatim.
Transcriptions were then subjected to an inductive the-
matic analysis using methods drawn from Braun and
Clarke.37 Data were summarized with short, one or two
word codes, at the sentence-to-paragraph level. Codes
were then compared to one-another and grouped,
which led to the construction of broader themes that
captured the core topics and concerns emerging from
the data.
Results
Fifty-eight participants were identified for potential
inclusion. Twenty of these chose not to join (due to
reasons such as not feeling drooling was severe
enough; not having time to commit to research).
Thirty-eight consented to participate. During the trial,
10 participants left the study. Five stated reasons of ill
health, four felt the study was too much for them to
manage at the time, and one gave no reason. The data
analyzed came from the 28 remaining participants (10
female). Compliance levels for filling out diaries varied.
Out of a possible 6699 diary entries, 5069 (76%) were
provided. The demographic and case history informa-
tion can be viewed in Table 1. No significant biases
were observed between the two groups with regard to
any of the variables investigated.
Intervention vs. no intervention
Results for the first and second assessments with the
no-intervention group, and assessments for the imme-
diate intervention group before and at end of interven-
tion, appear in Table 2. There were no statistically
significant differences between the immediate and
delayed intervention groups at the initial baseline T
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assessment. There were no significant changes in
ROMP-S, UPDRS 2.2, or Diary reports (VAS meas-
urements) for the no-intervention group during the four
weeks of no treatment. There were also no statistically
significant changes to ROMP-S and UPDRS 2.2 in the
intervention group when comparing pre- versus termin-
ation of treatment. Patient perceived changes on the
VASs did show significant improvement in the interven-
tion group for overall severity, but for frequency of
drooling improvement was borderline (p¼ 0.06) and
perceived amount of time (duration) of drooling did
not alter significantly.
Comparison of pre- and post-treatment scores across
all participants
Given that there appeared to be no placebo effect in the
delayed intervention group during the no intervention
phase (i.e., no significant improvement in any scores),
once both groups had completed intervention their
scores were combined to provide a larger group
(n¼ 28) for comparison of pre- versus post-treatment
versus follow-up assessment.
Between treatment termination and four-week
follow-up assessment four participants left the study
(two moved on to Botox treatment immediately after
the intervention ended, one experienced significant
health decline and one moved abroad). This left 24 par-
ticipants available for longer term follow-up assessment
comparisons. Outcomes are summarized in Table 3.
ROMP-S ratings saw no significant change compar-
ing scores at pre- versus at termination of treatment.
UPDRS 2.2 ratings showed a trend toward significance
but were still statistically non-significant. VAS patient
perceptions of change in overall severity, duration, and
frequency of drooling all evidenced significant
improvements.
To examine whether scores returned to baseline
status once intervention finished, baseline scores were
compared with four weeks post-treatment assessments.
ROMP-S demonstrated a move toward significance
(but was still not statistically significant), while
UPDRS 2.2 now showed a significantly better status.
The VAS ratings all showed strongly significant
improvements, including after adjustments for multiple
testing. The findings suggest maintenance or even
improvement of status during the follow-up phase.
Exit interviews
Twenty-seven participants were available for exit inter-
view. One participant had a significant health decline
and was thus unavailable. Interviews lasted mean
17:03min (shortest 6:29-longest 36:37). Following pro-
cedures outlined in the Methods section, 26 thematic
codes applied to the data. A total of 312 extracts of
transcript were assigned these codes (ranging from 1
to 22 extracts per code). A total of four higher level
themes were then constructed from this qualitative
data analysis, which are summarised below.
The first theme to arise was the impact of drooling
on the lives of the participants. By far, the most dis-
cussed impact of drooling issues pre-treatment was
embarrassment (13/27), with several participants
discussing emotional distress ‘‘It really dominated my
life . . . it was most distressing, psychologically distress-
ing . . . it clearly ruled my thinking . . . in that I was
always clasping this grubby handkerchief just in case’’
(P14), and social withdraw, ‘‘At least once a day it
would happen. I was out with company and it made me
Table 2. Assessment and diary results for both groups, from assessment 1 to assessment 2.
Assessment
Delayed group (n¼ 11) Intervention group (n¼ 17) Significance of between
group difference
Assessment
point 1 (T0)
Median (IQR)
Assessment
point 2 (T1)
Median (IQR)
Assessment
point 1 (T0)
Median (IQR)
Assessment
point 2 (T1)
Median (IQR) Mann–Whitney U test
ROMP–saliva 20 (17–25) 19 (17–30) 22 (16–23) 22 (17–25.5) U¼ 83.0, z¼ 0.497, p¼ 0.619
UPDRS 2.2 (saliva and
drooling subtest)
3 (1–3) 3 (1–3) 3 (3–4) 3 (2–4) U¼ 69.0, z¼ 1.212, p¼ 0.225
Drooling diary
Severity 1 (0–4) 1 (1–5) 3 (1.5–5) 1 (0–2.5) U¼ 39.5, z¼ 2.575, p¼ 0.010
Duration (No. minutes
drooling occurred in 1 h)
1 (0–5) 2 (0.5–10) 5 (1–11) 1 (0–4.5) U¼ 63.0, z¼ 1.440, p¼ 0.150
Frequency (No. instances in 1 h) 1 (0–4) 3 (1–4) 3 (1–4.5) 1 (0–3) U¼ 54.0, z¼ 1.876, p¼ 0.061
UPDRS: Unified Parkinson’s Disease Rating Scales.
Please note that lower scores indicate a lowered perceived severity in the diary, or lower impact of symptoms in the Parkinson’s Disease Questionnaire
(PDQ-39) subtests, Radboud Oral Motor Inventory for Parkinson’s disease (ROMP)–Saliva and Unified Parkinson’s Disease Rating Scale (UPDRS) 2.2.
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feel very embarrassed. I tend to withdraw, avoid going
out really. Eat on my own. I am pretty strict about man-
ners, and I thought it looked horrible’’ (P12). Several
participants (4/27) also discussed physical discomfort
that they experienced—constant wetness, changing of
handkerchiefs, painful sores around the mouth.
The second theme related to challenges around pre-
vious experiences of drooling treatment. Several partici-
pants (3/27) had previous experience of Botox;
however, for a lot of participants (8/27), Botox was
not an option they would have considered. These par-
ticipants discuss a lack of willingness to take additional
medication; ‘‘when I saw the consultant they said I could
go and have Botox, an injection. I didn’t want to take any
more drugs’’ (P22). Botox was associated with words
such as ‘‘toxic’’ (P25) and ‘‘poison’’ (P26) and there
was a clear preference for avoiding it, and other add-
itional medication, if possible; ‘‘I think if you can have
something that avoids taking drugs I think that’s great’’
(P4). These participants, unsurprisingly, preferred the
PDCue as a behavioral treatment option; ‘‘I’d rather
have the watch’’ (CP7).
Theme 3 related the effect of the PDCue on drooling.
Of the 27 interviewed participants, there was a reported
positive effect for 22, indicating that the majority of
participants successfully engaged with the intervention
and found it to be a worthwhile option for supporting
the self-management of drooling. Participants also dis-
cussed emotional benefits which arose as a result of the
PDCue intervention, including improvements to self-
esteem, confidence, and feelings of control.
The final theme related to reports of generalization
and habituation. There were several cases of partici-
pants reporting a generalization effect, wherein they
felt an increase in swallowing frequency was being car-
ried over to times when they were not wearing the
PDCue (9/27). P4 said ‘‘Even when I wasn’t wearing
the [PDCue] every now and again I think, ‘Oh yes, you
haven’t swallowed. I need to swallow’.’’ P3 also noted
‘‘even when I wasn’t wearing it I was much more con-
scious of it.’’ Although unexpected, P26 also discussed
an improvement to his night time drooling ‘‘I’ve hardly
been drooling at all. No, I haven’t. Even during the night
I haven’t been.’’
There were a small number of participants (3/27)
however who reported becoming habituated to the
cues, e.g., P10 ‘‘there were occasions when I had the
watch on, I seemed to have got so used to it that I
didn’t get any indication.’’ However, these participants
reported a positive effect from the intervention, despite
this habituation.
Discussion
This pilot study aimed to explore the feasibility, usabil-
ity, and acceptability of wearing a wrist-worn vibratory
cueing device to improve drooling in people with
Parkinson’s, and to establish whether there was evi-
dence of an effect of the device on drooling severity,
frequency, and impact. Twenty-eight people completed
a month-long intervention with the device, using it for
an hour a day. Altogether they showed significant
improvement on severity (p¼ 0.031), frequency
(p 0.001), and duration (p¼ 0.001) of drooling when
comparing results from the self-reported VASs col-
lected pre- and post-intervention. These improvements
were also seen to remain at follow up assessment four
weeks post-treatment compared to their pre-interven-
tion baseline. A significant improvement was also
seen in the UPDRS 2.2 saliva subtest (p¼ 0.010)
when comparing the pre-intervention and follow-up
assessment time points. Based on this, we conclude
Table 3. Assessment and diary results for the entire intervention group (n¼ 28) for pre-, posttreatment, and follow-up results.
Assessment
Entire group (n¼ 28) Significance of difference
Assessment
point 1 (T0)
Median (IQR)
Assessment
point 2 (T1)
Median (IQR)
Assessment
point 3 (T3)
Median (IQR)
Assessment
points 1 (T0)
to 2 (T1)
Assessment
points 1 (T0)
to 3 (T2)
ROMP–saliva 20.5 (16–23.75) 20 (16.25–24.75) 17 (15–23.5) Z¼ 0.275,p¼ 0.783 Z¼ 1.800,p¼ 0.072
UPDRS 2.2 (Saliva and
drooling subtest)
3 (3–4) 3 (2–4) 2 (1–3) Z¼ 1.801,p¼ 0.072 Z¼ 2.569,p¼ 0.010
Drooling diary
Severity 3.14 (2.42) 1.18 (1.57) 1.14 (1.51) Z¼ 2.151,p¼ 0.031 Z¼ 2.809,p¼ 0.005
Duration (No. minutes
drooling occurred in 1 h)
7.45 (10.64) 4.75 (11.55) 1.86 (2.73) Z¼ 3.362,p¼ 0.001 Z¼ 2.631,p¼ 0.009
Frequency (No. instances in 1 h) 4.18 (5.68) 1.80 (2.32) 1.16 (1.47) Z¼ 3.982,p< 0.001 Z¼ 3.606,p< 0.001
Please note that lower scores indicate a lowered perceived severity in the diary, or lower impact of symptoms in the Parkinson’s Disease Questionnaire
(PDQ-39) subtests, Radboud Oral Motor Inventory for Parkinson’s disease (ROMP)-Saliva and Unified Parkinson’s Disease Rating Scale (UPDRS) 2.2.
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there is some evidence to indicate that the device can be
successful in improving saliva control, not only when
wearing the PDCue but also when not using it or after
intervention has been withdrawn.
Comments from the interviews confirm that people
are disturbed by their drooling and that lesser drooling
brings benefits for psychosocial well-being. Participants
were satisfied with manipulating the device and found it
acceptable to wear. They perceived the gains seen made
wearing the device worthwhile. This is further reflected
in comments participants made in the exit interviews
concerning the perceived positive effects of the interven-
tion device. Responses showed that 22/27 participants
explicitly reported that they had noticed benefits
to their drooling, with several stating that it was a pref-
erable treatment option to other pharmaceutical inter-
ventions. In a larger trial, it is unlikely that this
interview-based approach could be undertaken at
scale. The development of a questionnaire, drawing
on the themes outlined from the qualitative data
could be an approach to capturing data of this kind.
The lack of positive change in the delayed treatment
group during their no-intervention phase suggests that
change was not accounted for by a placebo effect from
being recruited to the study, being assessed, completing
the diary exercise, nor from receiving information
about drooling and drooling interventions in general.
There was no improvement despite written (in the study
information pack) and oral discussion that more fre-
quent swallowing may benefit saliva loss. While the
present data suggest placebo effect does not play a sig-
nificant role here, in a definitive trial a more active
comparator condition should be introduced.
Our results showed a measurable change in score in
the UPDRS item for drooling, between baseline and
four-week follow-up, lending additional weight to the
improved VAS responses that participants provided.
However, we did not observe any significant differences
in the ROMP-S overall score. This may indicate that
the types or level of changes experienced over the inter-
vention period were not sufficient for this tool to cap-
ture. It could be that employing an overall score across
multiple dimensions rather than analyzing each item
separately masked significant gains in some areas. For
instance, there may have been no change in night time
drooling score, or even, after a short period, no shift in
overall impact. Nevertheless, frequency of having to
wipe the mouth or perceived excessive saliva in the
mouth may have altered, but these improvements
failed to make a significant difference in overall score
against the non-altered variables. A similar factor may
be at work in the lesser (compared to VASs) sensitivity
to change of the UPDRS saliva item, since this scale
combines several features which might actually vary
independently (e.g., day vs. night drooling; perceived
excess saliva in mouth; frequency vs. severity) in one
scale. Significant improvement in one sub-dimension
may be missed if the other dimensions do not alter.
Further analyses of individual items prior to a definitive
trial may aid in separating out which aspects of drooling
are more or less susceptible to influence through cueing.
A factor to consider for a larger trial is data complete-
ness for the diaries. We had a 76% completion rate across
the study. Although this is not dissimilar to other studies
(e.g., Hauser et al.33), a larger trial would need to consider
the time requirements of participants and the burden of the
study to self-report. We make the suggestion that complet-
ing the diary throughout the entirety of the study is not
required. Only completing the diary for one-week pre- and
post-intervention (and again at follow up) would be
enough in a follow up trial, as these were the results that
we eventually focused on in our analysis.
Self-reported diaries are heavily used in clinical
research as a way to monitor the progress of treatment
and log patients’ activities over time, without the require-
ment for a researcher to be present, despite long-standing
reported issues with compliance (e.g., Montgomery and
Reynolds34 and Stone et al.35). Recent research into tools
to support self-report in Parkinson’s research has pro-
vided clear recommendations for improving practice,
with Vega et al. finding 99% compliance with their
paper-based tool measuring self-reported symptoms
over several months with a small number of partici-
pants.38 However, another solution would be to introduce
usage logs, collected automatically by the device, which
would also provide an indication of participant compli-
ance without the need for the diary.
The body of literature exploring cueing for drooling
as a symptom is minimal, with small-scale preliminary
work by Marks et al.22 and Marron et al.23 being the
only examples exploring this space. As such, our work
builds upon this nascent body of literature to provide
additional evidence that cueing for drooling might be an
effective way to manage the symptom, with the qualita-
tive aspects of our study additionally demonstrating
reports around increased feelings of control, confidence,
and self-esteem post intervention. In addition, we build
on our previous work24 to report that acceptance and
usability of our device has been confirmed with a larger
and more varied group of participants over a longer
period of time. Our cueing approach warrants further
exploration in a larger scale trial.
Study limitations
There are several provisos in interpreting the current
data. Firstly, one assumes that participants were wear-
ing the devices as requested, for a designated hour each
day. However, we did not collect precise usage logs.
In future work, there would be benefit in utilizing a
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more objective approach, e.g., through digital usage logs
collected directly through the device (i.e., using an accel-
erometer to provide data on when the device is switched
on and being used). Secondly, we asked participants to
self-select an hour within which to self-monitor their
drooling, at times when drooling was a problem. While
participants may have selected a self-perceived period of
more susceptibility to drooling, it remains unclear how
severe their chosen hour might have been. Further
laboratory-based work, employing objective measures of
physiological drooling (e.g., objective swallow frequency
measurement, or saturated gauze weight measurement)
would add insight into whether or not orally retained
saliva objectively decreased through use of the device.
This would also remove, at least in laboratory conditions,
the use of self-report diaries that may be open to recall
bias. For field-testing, employing devices capable of mea-
suring swallowing events in naturalistic situations (e.g.,
using an in-ear microphone) would be beneficial.
Finally, although 30 participants were the sample
size intended for this first stage feasibility trial, we did
not have matched numbers between the delayed and
immediate groups. The intention was to have 15 par-
ticipants in each, but time constraints meant that we
were unable to fully recruit to our delayed group (with
four participants remaining). We made a decision to
include a final two participants in the study as immedi-
ate intervention participants. Future studies imple-
menting two treatment strands should not have this
problem in future work; however, future researchers
should also consider randomisation approaches that
allow for equal participant numbers throughout the
recruitment process (e.g., even vs. odd participant num-
bers to each strand). In addition, while the results of
our pilot work delivered some positive outcomes, suffi-
cient to suggest the cueing device may be effective, a
more definitive answer awaits a trial involving larger
numbers in a more highly powered study and with an
active intervention comparator.
Conclusions
This study has indicated that our cueing device was
acceptable and usable, and that the intervention could
be a feasible first step for clinicians, before moving on
to pharmaceutical options, which have been shown to
have potential complications. While the next step of
this research will require a larger multi-center trial to
elucidate whether these results are replicable and
clearer in a larger population, and to look at the char-
acteristics of responders vs. non-responders to the
treatment, the information presented within this paper
has provided important, preliminary data around the
effect that the cueing intervention could have and issues
to address in the development of outcome measures.
Clinical messages
. Providing a regular vibratory cue, through the
PDCue device was shown to be an effective treat-
ment for reducing perceived drooling in the great
majority of participants.
. Participants accepted PDCue and remained moti-
vated to self-manage their drooling with the device.
. Further studies are needed to confirm the beneficial
effects that we observed and for the refinement of
outcome measures.
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